Titan Pharmaceuticals Inc. Company Name:
TTNP Stock Symbol:
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's non-clinical development of a ProNeura™ based six-month implantable...
Titan Pharmaceuticals, Inc. (TTNP) Q2 2019 Earnings Conference Call August 14, 2019 04:30 PM ET Company Participants Sunil Bhonsle - President & Chief Executive Officer Jennifer Kiernan - Executive Assistant to CEO & Investor Communications Coordinator Marc Rubin - Execut...
Titan Pharmaceuticals (NASDAQ: TTNP ): Q2 GAAP EPS of -$0.38 misses by $0.11 . Revenue of $0.5M (-81.3% Y/Y) misses by $0.43M . Press Release More news on: Titan Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,